TBI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TrueBlue Inc (TBI) is not a strong buy right now for a beginner focused on long-term investing, even with $50,000-$100,000 to deploy. The stock has some supportive signals from its moving averages and the acquisition-related news flow, but the absence of Intellectia buy signals, weak short-term technical momentum, and only neutral insider/hedge fund activity make this more of a wait-and-see situation than an immediate purchase. If the goal is to buy without waiting for a perfect entry, this is still not compelling enough to call a buy today.
TBI is trading at 6.12, slightly below the nearby resistance zone (R1 6.02 was already tested, with R2 at 6.238) and above the pivot level of 5.669, which keeps the broader setup mildly constructive. The moving average structure is bullish (SMA_5 > SMA_20 > SMA_200), but momentum is not confirming strength: the MACD histogram is slightly negative and contracting, which points to fading upside momentum. RSI_6 at 76.524 suggests the stock is extended rather than offering an attractive fresh entry. The near-term pattern data also looks weak, with expected next-day and next-week performance slightly negative on average.
suggests the longer-term trend is still constructive."]
["No Intellectia AI Stock Picker signal today.", "No SwingMax buy signal recently.", "MACD histogram is below zero and weakening, showing poor momentum.", "RSI is elevated, indicating the stock is extended after recent strength.", "Options volume leans bearish with a 2.0 put-call ratio.", "Hedge funds and insiders are both neutral, with no meaningful accumulation signal.", "No recent congress trading data available.", "The stock\u2019s near-term pattern analysis implies slightly negative performance over the next day and week."]
No usable latest-quarter financial snapshot was provided because the financial data section returned an error. As a result, there is no confirmed revenue, earnings, or margin trend available here. Based on the provided data alone, I cannot credit the stock with a recent fundamental acceleration or quarter-over-quarter growth improvement.
No analyst rating or price target trend data was provided in the dataset, so there is no evidence here of a clear Wall Street upgrade cycle or rising target pattern. From the available information, the pro view is limited to takeover-related optimism and the bullish moving average setup. The con view is that momentum, options flow, and ownership signals do not confirm a strong upside thesis.
